Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines

Abdel Hady A Abdel Wahab1*, Eman G Ayad2, Mohga S Abdulla2, Hayat M Sharada2, Abeer M Ashmawy1

Abstract

Objective: The purpose of the current study was to investigate the possible anti-tumor effect of miR-27a inhibitor in combination with Sorafenib (SOR) on cell proliferation and apoptosis of hepatocellular carcinoma cell lines. Methods: Transient transfection by oligo-miR27a inhibitor (miR-27ai) was used in this study for targeting the oncogenic miR-27a in HepG2 and Huh7 cells followed by SOR treatment. Cell viability was measured using SRB assay. The cell cycle and apoptosis were assessed by flow cytometry assay. Moreover, the level of oncogenic miR-27a was evaluated in 19 tissues of primary HCC patients as well as cell lines using qRT-PCR assay. Finally, caspase-3 activity was determined using ELISA assay. Results: Significant up-regulation of miR-27a expression was reported in HCC patients confirming its oncogenic role. Treatment of cells with SOR following transfection with miR-27ai declined cell viability significantly compared with either control or single agent treatment (p≤0.05). Highly significant decreasing in the number of cell in S-phase associated with increasing in G0-phase was also observed. Furthermore, apoptotic rate was highly significantly increased for transfected/SOR treated cells (p≤0.01). Finally, combination treatment demonstrated a significant elevation of caspase-3 activity level in both cell lines examined. Conclusion: The present data demonstrated targeting miR-27a enhances the anti-tumor effect of SOR in HCC cell lines considering as one of the promising therapeutic targets for advanced HCC management.

Keywords: Sorafenib- HCC- miRNAs- miR-27a- HepG2 cells- Huh7 cells
of the aggressive traits of the disease including tumor progression, metastasis and drug resistance (Zhang et al., 2017; Li et al., 2017).

Interestingly, various studies spotted lights on changes in miRNA expression profiles in many cancer types in response to much therapeutics including sorafenib. It has been shown that miR-26a plays a crucial function for inhibiting angiogenesis and metastasis via targeting VEGFA and HGF. Its low expression was reported in metastatic HCC tissues compared with their corresponding normal referring to its possible therapeutic target against metastasis (Yang et al., 2014). Another study showed an enhancement of sensitivity of HCC cell lines to doxorubicin and vincristine treatment upon upregulating miR-122 expression level through suppressing Bcl-w and cyclin D1 protein levels that are involved (Xu et al., 2011).

miR-27a, one of the miRNA-27 family, was located on chromosome 19. Growing evidence has confirmed its vital role in regulating various biological processes in human cells including proliferation, migration, invasion and metastasis. Furthermore, its clinical significance as a therapeutic agent of cancer and drug sensitivity. It has been demonstrated that miR-27a was significantly overexpressed in different type of tumors including HCC refereeing its oncogenic property (Li et al., 2015). Meanwhile, it behaves as a tumor suppressor in other types of tumor (Bao et al., 2014). Previous study demonstrated that suppression of miR-27a level sensitized colorectal stem cells to TRAIL (Zhang et al., 2017).

Therefore, the aim of the present study was to explore the anti-tumor effect of miR-27a inhibitor in combination with sorafenib treatment on HCC cell lines (HepG2/ Huh7) that might provide a useful strategy for enhancing hepatocellular carcinoma treatment.

Materials and Methods

Materials

Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), Penicillin and streptomycin were obtained from (Sigma-Aldrich Chemical Co., St. Louis, MO, USA). Sorafenib was purchased from the Bayer Corporation (West Haven, CT). For a 10 mM stock, the 10 mg reconstituted in 1.57 ml DMSO. The final concentration of DMSO in medium was 0.1% (v/v).

Cell lines and tissue specimens

Human hepatocellular carcinoma cell lines HepG2 and Huh7 were purchased from VACSERA (The National Holding Company for Biologics and Vaccines, Cairo, Egypt). The two cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin then incubated at 37°C in a highly humidified atmosphere incubator with 5% (v/v) CO₂ and 95% air. The cell lines regularly sub-cultured to be in there exponential growth rate.

Nineteen formalin fixed paraffin embedded (FFPE) specimens were obtained from newly diagnosed primary HCC patients at the Egyptian National Cancer Institute, Cairo University. Five FFPE specimens were collected from healthy liver donors’ prior transplantation as controls. A written informed consent was obtained from the individual included in the study and the study was approved by the Institutional Review Board of the Egyptian National Cancer Institute, Cairo University.

Cell proliferation assay

Sulphorhodamine-B (SRB) assay (Sigma-Aldrich Chemical Co., USA) was conducted for assessing the cytotoxic effect of Sorafenib on the growth of HuH-7 and HepG2 cells. Cells were seeded in plate 96-multiwell plate (1X10⁴ cells/well) in fresh medium and cultured for 24 hrs treatment until reaching 50–60% confluence, then treated with different concentrations of Sorafenib (3, 4, 8, 16 and 32µM) for 48 hrs to determine the most effective dose to be combined with miR-27a. Following treatment, cells were fixed with 50 µl cold 50% TCA for 1 h at 4°C. Wells were washed once with distilled water and stained for 30 min at room temperature with 50 µl 0.4% SRB dissolved in 1% acetic acid for 10 min. Unbound SRB was removed by washing five times with 1% acetic acid. After dried, protein-bound dye was extracted with 100 µl of 10 mM Trisbase (pH 10.5). Control cells were treated with 0.1% DMSO alone and the absorbance was measured at 570 nm using a microplate reader (Tecan SunriseTM, Germany). Each treatment was done in three independent experiments.

Anti-miR-27a transfection

HepG2 and Huh7 were incubated at 37°C in a 96-well plate (1X 10^⁴ cells/well). Just prior to transfection, the media were replaced with 50 µl serum free media. MiR-27a inhibitor and miR-NC (purchased from Qiagen, Germany) was conducted for assessing the cytotoxic effect of Sorafenib on the growth of HuH-7 and HepG2 cells. Cells were seeded in plate 96-multiwell plate (1X10⁴ cells/well) in fresh medium and cultured for 24 hrs treatment until reaching 50–60% confluence, then treated with different concentrations of Sorafenib (3, 4, 8, 16 and 32µM) for 48 hrs to determine the most effective dose to be combined with miR-27a. Following treatment, cells were fixed with 50 µl cold 50% TCA for 1 h at 4°C. Wells were washed once with distilled water and stained for 30 min at room temperature with 50 µl 0.4% SRB dissolved in 1% acetic acid for 10 min. Unbound SRB was removed by washing five times with 1% acetic acid. After dried, protein-bound dye was extracted with 100 µl of 10 mM Trisbase (pH 10.5). Control cells were treated with 0.1% DMSO alone and the absorbance was measured at 570 nm using a microplate reader (Tecan SunriseTM, Germany). Each treatment was done in three independent experiments.

Quantitative RT-PCR

Total RNA from cell lines and FFPE sections was purified using miRNeasy Mini and miRNeasy FFPE kits (Qiagen, Germany) following manufacture instructions. cDNA was synthesized from 1 µg of RNA using miScript RT II kit (Qiagen) according to the supplied protocol. The expression level of miR-27a was determined using SYBER Green reagent kit (Qiagen). About 5 ng of cDNA was used as template in a 10 µl PCR reaction containing 1X SYBR Green master mix, 1X miRNA specific forward primer, and 1X universal primer. All the RT-qPCR reactions were performed on Viia7 real-time PCR system (Applied Biosystems, USA). All samples were performed in triplicate. U6 snRNA was used as an endogenous control for normalization. Data were expressed as fold change, using the 2−ΔΔCt method.

Enzyme-linked immune sorbent assay for Caspase-3

The concentrations of Caspase-3 level was determined on cell lysate of transfected/untransfected followed with sorafenib treated cells for 48 hrs comparing to negative
control using ELISA kit (BioSource, CA, USA) according to the manufacturer’s instructions. All samples were assayed in triplicate and standard curve was plotted and used to calculate the concentrations.

**Cell cycle assay**

After 48 hrs treatment with sorafenib, the transfected/untransfected cells and negative control were harvested and washed twice with cold PBS. The cell suspension was adjusted to a concentration of 1 X 10⁶ cells per ml. Cells were fixed in 100 % ethanol at 4°C overnight then cells were resuspended in 200 µL 1X propidium iodide (PI), incubated at 37°C in the dark for 20 – 30 min placed on ice. G0 /G1, S and G2/M phases’ populations were detected by PI detector with flow cytometry (Beckman Coulter, USA) and analyzed by flowing software version 2.5.1(Turka centre of biotechnology, Turka uni, Finland).

**Cell apoptosis analysis**

Annexin V-FITC/PI (fluorescein isothiocyanate/propidium iodide) apoptosis detection kit (BestBio, Shanghai, People’s Republic of China) was used according to the manufacturer’s protocols for detection of apoptotic cells via flow cytometry in transfected and untransfected cells before and after sorafenib treatment comparing to negative control. Briefly, cells were collected and centrifuged for 10 min at 1,200 rpm. After washing with PBS, cell suspension was adjusted to a concentration of 1 X 10⁶ cells per ml and stained with 10 µL of Annexin V-FITC for 15 minutes and 5 µL of PI for 5 minutes at 4°C in the dark. Cells were then analyzed using FITC signal detector and PI detector with flow cytometry (Beckman Coulter, USA), and flowing software version 2.5.1 (Turka centre of biotechnology, Turka uni, Finland).

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism version 7 for windows (GraphPad Software, CA, USA). Data are presented as mean ± standard deviation (SD). Multiple comparisons were carried out using one way analysis of variance (ANOVA) followed by Tukey test for post-hoc. Statistical significance was acceptable at a level of p-value < 0.05. The two-tailed Student’s t test was used for all real time RT-PCR, cell cycle, apoptosis and caspase-3 level data. P-value threshold < 0.05 was considered significant.

**Results**

Effect of sorafenib on cell proliferation

Both cell lines used in the present study (HepG2/Huh7) demonstrated slightly difference in their sensitivity to sorafenib. HepG2 cells exhibited more sensitivity rather than Huh7 cells after treatment for 48 hrs. The calculated IC50 for HepG2 and Huh7 cells was 8 µM and 10 µM respectively. Based on this data, sub lethal doses of sorafenib (IC₂₀ and IC₃₅) were selected for treatment of cells in the subsequent experiments.

Effect of combined treatment of miR-27a inhibitor/ Sorafenib on proliferation rate of HepG2 and Huh7 cell lines

Combining treatment of Anti-miR-27a and sorafenib was performed to determine their anti-tumor effect on HepG2 or Huh7 cells proliferation. A significant decreasing in proliferation was reported in both cell lines (HepG2 and Huh7) transfected with miR-27a inhibitor alone by 37% and 18% (Figure 1) compared with NTC (p < 0.05). While, combined treatment of miR-27a inhibitor with sorafenib (IC₃₅) resulted in a significant inhibition in cell viability by 40% and 71% in HepG2 cells and Huh7 respectively compared to NTC (p < 0.05). The combined treatment of miR-27a inhibitor with higher dose of sorafenib (IC₅₀) resulted in a higher significant inhibition in cell viability by 52.5% and 76.5% in HepG2 cells and Huh7 respectively compared to NTC (p<0.05).

Figure 1. Effect of different doses of sorafenib (IC₂₀ and IC₃₅) on the surviving fraction of HepG2 and Huh7 cells transfected with 50nM miR-27a inhibitor for 48 hrs. The results are expressed as the mean±SD of 3 independent experiments. The statistical significance of the results was analyzed using one way ANOVA followed by Tukey multiple comparison test. a Significantly different from controls (control, NTC and DMSO), b from sorafenib only treated cells (p≤ 0.05).
Negative control and solvent (DMSO) did not show any significantly effect on cell viability for both cell lines. The data revealed that combining the antisense miR-27a with sorafenib could enhance the antitumor effect of sorafenib through declining the number of viable cells in both cell lines. Accordingly, we selected the best anti-proliferative effect of sorafenib (IC$_{35}$) with miR-27ai for the analysis of cell cycle, apoptosis and caspase-3 assays.

**Effects of Sorafenib or miR-27a inhibitor on Expression level of miR-27a in HepG2 and Huh7 cell lines**

Using quantitative RT-PCR assay, a significant up-regulation of miR-27a expression was reported in RNA isolated from FFPE specimens of 19 primary HCC patients analyzed compared with their corresponding healthy controls (Figure 2). The mean fold change recorded was about 10.072 (P<0.0206). This data confirmed overexpression of miR-27a in primary HCC tissues that refer to its oncogenic function.

Moreover, we investigated whether sorafenib or miR-27a inhibitor influence the expression level of miR-27a in HepG2 and Huh-7 cell lines. As shown in Figure 3, a significant decrease in miR-27a expression level was reported for both cell lines after treatment with sorafenib where log fold changes of miR-27a level were -0.5 and -1.5 for both cell lines respectively (P<0.01). Furthermore, highly significant down-regulated (-3.2 and -2.8) miRNA-27a expression was detected in both cell lines after transfection with miR-27ai indicating its successful transfection process (P<0.01).

**Effect of combined treatment (miR-27ai and sorafenib) on cell cycle and apoptosis of HepG2 and Huh7 cell lines**

We investigated the effect of combination of anti-miR-27a and sorafenib (IC$_{35}$) on cell cycle progression using flow cytometry for HepG2 and Huh7 cell lines. A significant decreasing in the number of cells in S-phase was reported when cells treated with miR-27ai or sorafenib alone for both cell lines (p<0.05). Furthermore, a significant decreasing was recorded when cells exposed to combined treatment (miR-27ai+sorafenib). A significant increasing was also reported in number of cells in sub G0-phase for combined treated cells (p<0.05) compared with control untreated cells (Figure 4).
In this study we next evaluated the apoptotic induction in HepG2 and Huh7 cells which co-treated with anti-miR-27a followed by sorafenib ($IC_{50}$) via assessment the percentage of apoptotic cells by flow cytometry. Significant increase in apoptotic cell populations in HepG2 and Huh7 cells was observed when treated with sorafenib alone (p<0.05) and this rate demonstrated highly significant for cells transfected with miR-27a inhibitor followed by treatment with sorafenib compared with control cells (p<0.01). The percentage of apoptotic rates recorded for HepG2 transfected with miR-27ai, sorafenib alone, and combined treatment were about 6.15%, 23.1% and 65.9 versus control 1.21% respectively. Furthermore, the percentage of apoptotic rates for Huh7 cells recorded were 0.87%, 33.3% and 70.1% versus control 0.32% respectively as indicated in Figure 5.

To further verify the anti-tumor effect of miR-27ai+sorafenib induced cell apoptosis, we examined the level of caspase-3 activity, a hallmark of apoptosis, on both cell lines using Elisa assay. As shown in figure 6, there is a significant increasing in its level for miR-27ai transfected cells or sorafenib treated cells alone which became highly elevated for combination treated cells compared with either of control or single agent treatment (p<0.05).

**Discussion**

Therapeutic modulation of a single miRNA may affect many pathways simultaneously to achieve more clinical benefit (Ebert et al., 2007). Hence targeting aberrantly expressed miRNA is logical and attractive. The widespread overexpression of miR-27a in cancer has led to the belief that miR-27a is an oncogenic microRNA. Cell culture and animal experiments supported this speculation, showing that the down-regulation of miR-27a expression can suppress cell proliferation and slow tumor growth. Some reports demonstrated the oncogenic role of miR-27a which plays important role in the development of HCC.
and might thus be a new therapeutic and prognostic target in HCC patients (Li et al., 2015).

Several recent studies confirmed the protooncogenic characteristic of miR-27a in different types of cancer. It has been shown that overexpression of miR-27a was associated with high cell proliferation and metastasis in gastric cancer cells through mediating suppression of PH domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) leading to stimulation of the AKT/GSK3B pathway (Ding et al., 2017). Moreover, overexpression of miR-27a enhanced tumor metastasis by stimulating epithelial-mesenchymal transition process in breast cancer which added further evidences for its potential application in cancer therapy (Jiang et al., 2018). High expression of miR-27a level detected in tissues of primary HCC patients in the current data are consistent with that previously reported studies confirming its oncogeneic role in HCC.

The discovery of targeted therapy with multi-tyrosine kinase inhibitors, such as sorafenib has set a breakthrough for patients with advanced cancer. Its antitumor mechanism involving the inhibitor mostly known pathways associated with hepatocarcinogenesis include the Ras/Raf/ MAP/ERK, the PI3K/Akt/mTOR, the Wnt/β-catenin and the JAK/STAT pathways (Wilhelm et al., 2005) but its mechanism of action still has not been fully elucidated. Emerging evidences considering miRNAs as important key players in HCC pathogenesis. Numerous experimental and clinical studies revealed that the aberrant expression of miRNAs is associated with the progression of hepatocellular carcinoma (Callegari et al., 2013; Lu et al., 2005). Moreover, various studies highlighted changes in miRNA expression profiles in response to sorafenib and other therapeutics (Peveling-Oberhag et al., 2015; Stiuso et al., 2015). A study done on HCC cells demonstrated that miR-142-3p sensitised cells to sorafenib by promoting apoptosis and inhibiting cell growth and proliferation via targeting autophagy related 5 (ATG5) and autophagy-related 16-like 1 (ATG16L1) which are the main targets of autophagy regulating miR-142-3p (Zhang et al., 2018). Declining of miR-221 overexpression level using its inhibitor modulate sensitized HCC cells via induction of caspase-3, a pro-apoptotic target of miR-221 (Forner et al., 2017). It has been indicated recently that miR-140-3p can enhance the antitumor effect of sorafenib via targeting pregnane X receptor (PXR) resulting down-regulation of drug-resistance related genes in HCC cells (Li et al., 2018).

We explored the feasibility of regulation of miR-27a using chemically modified anti-miR Oligos alone and in combination of Sorafenib in HCC cells. Our data showed that combining of antisense miR-27a Oligos with sorafenib sensitized HepG2 and Huh7 to sorafenib-induced cell death compared to sorafenib-only treated cells and controls, indicating that antisense miR-27a could potentiate the antitumor effect of sorafenib through declining the number of viable HCC cells in vitro. Previous study demonstrated using a lentiviral vector to stably expression of anit-miR-27a targeting the oncogenic miRNA declines proliferation of glioma cell line suggesting its potential role for suppression of malignancy (Feng et al., 2012). Xu et al., (2013) proposed that inhibition of miR-27a by its antisense oligo enhanced the response of ovarian cancer cell line SKOV3 to Genistein and decrease cell growth and metastasis by upregulating the Sprouty2, the putative miR-27a target gene.

An up-regulation of miR-27a was observed significantly in HCC tissues and different cell lines. Furthermore, its down-regulation using miR-27a inhibitor declined proliferation, induced apoptosis and blocked the G1/S cell cycle transition via targeting the 3'-untranslated region of peroxisome proliferator-activated receptor γ (PPARγ) using dual luciferase assay (Li et al., 2015). In gastric cancer cells, the reduction of miR-27a inhibited cell growth in both in vitro and nude mice assays which referred to its important role in cell proliferation (Zhao

![Figure 6. Caspase-3 Level (ng/ml) Hepatocellular Carcinoma Cells, HepG2 and Huh7, after Treatment with Sorafenib, miR-27a Inhibitor and Combination Compared with Control Untreated Cells Using Elisa Assay. Data were represented as mean values± SD for three independent experiments. The statistical significance of the results was analyzed using one way ANOVA followed by Tukey multiple comparison test. a Significantly different from controls (NC, NTC and solvent), b from sorafenib only treated cells (p≤0.05) considering significant significance.](image-url)
et al., 2011). Moreover, the most exciting finding in the present study was observed where a significant decline of cell count in S-phase of combined treated cells compared with either sorafenib or miR-27a inhibitor alone as shown by cell cycle analysis. Previous study done on the same cell lines reported reduction of cell counts in S phase upon treatment with anti-miR-27a oligonucleotides (Li et al., 2015).

Apoptosis is the one of dysfunctioning signaling pathways in HCC. The effects of administration of sorafenib on inducing apoptosis were investigated in many studies (Garten et al., 2019; Bahman et al., 2018).

In the current work, apoptosis analysis conducted by flow cytometry demonstrated a significant increase in apoptotic rate in cells treated with combination therapy compared with cells treated with either sorafenib or miR-27a inhibitor alone. Finding of Li et al., (2018) demonstrated a significant increase in apoptotic rate in HepG2 transfected with miR-27a inhibitor which verified the additional effect of combinational therapy (antisense miR-27a and sorafenib) on apoptotic rate of hepatocellular carcinoma cells.

To gain insight the molecular mechanisms in miR-27a mediated apoptosis, caspase-3 level was assessed in HepG2 and Huh7 transfected cells with antisense miR-27a. The results showed a significant increase in the caspase-3 in both transfected cells compared to controls. Remarkably transfected cells which co-treated with sorafenib demonstrated an enhancement in caspase-3 level compared to treatment with either sorafenib or miR-27a alone. The elevated level of the assessed caspase-3 upon transient transfection of miR-27a inhibitor in HepG2 and Huh7 might proposed to the negative correlation between miR-27a and APAF-1, a key mediator in cytochrome C-dependent apoptotic pathway (Zhang et al., 2017). The authors considered APAF-1 is the direct target of miR-27a.

Our finding data demonstrated that blocking miR-27a plays a crucial role in cell proliferation, cell cycle and apoptosis process in hepatocellular carcinoma cell lines. Furthermore, the antitumor effect of miR-27a inhibitor in combination with sorafenib on hepatocellular cell lines might alter its therapeutic strategy.

Acknowledgements

We would like to thank all the members of Abdel Wahab A.A. laboratory.

Author Contribution Statement

AA, conceived, designed and supervised the study. EA, performed the experiments and analyzed the data. AA, shared in study design and technical guidance of study. AA, MA, and HS, analyzing and interpretation of data as well as drafting the manuscript. All authors read and approved the final manuscript.

References

Bahman A, Abaza M, Khouishash S, Al-attiyyah R (2018). Sequence dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. Int J Mol Med, 42, 1695-1715.

Bao Y, Chen Z, Guo Y, et al (2014). Tumor suppressor gene microRNA-27a in colorectal carcinogenesis and progression by targeting SFPQ/Smad2. PLoS One, 9, e105991.

Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M (2013). Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Oncotarget, 6, 1167-78.

Ding L, Zhang S, Xu M, et al (2017). MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phoshatase 2. J Exp Clin Cancer Res, 36, 45.

Ebert MS, Neison JR, Sharp PA (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods, 4, 721-6.

Feng SY, Dong CG, Wu WK, et al (2012). Lentiviral expression of anti-miRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. Mol Med Rep, 6, 275-81.

Formari F, Pollutri D, Patrizi C, et al (2017). In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis. Clin Cancer Res, 23, 3953-65.

Garten A, Grohmann T, Kluckova K, et al (2019). Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1. Int J Mol Sci, 20, 4048.

Ghouri YA, Mian I, Rowe JH (2017). Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog, 16, 1.

Golabi P, Fazeli S, Otgonsuren M, et al (2017). Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore), 96, e5904.

Jiang G, Shi W, Fang H, Zhang X (2018). miR 27a promotes human breast cancer cell migration by inducing EMT in a FBXW7 dependent manner. Mol Med Rep, 18, 5417-26.

Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.

Li C, Miao R, Liu S, et al (2017). Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis. Oncotarget, 8, 28683–95.

Li J, Zhao J, Wang H, et al (2018). MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther, 11, 5885-94.

Li S, Li J, Fei BY, et al (2015). Micro-RNA-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor gamma. Chin Med J (Engl), 128, 941-7.

Liu CY, Chen KF, Chen PJ (2015). Treatment of Liver Cancer. Cold Spring Harb Perspect Med, 5, a021535.

Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.

Peveling-Oberhag J, Döring C, Hartmann S, et al (2015). Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clin Sci, 128, 29-37.

Stuspo P, Potenza N, Lombardi A, et al (2015). MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids, 4, e233.

van Malenstein H, Dekervel J, Verslype C, et al (2013). Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer
Wilhelm SM, Carter C, Tang L, et al (2005). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-7109.

Xu L, Xiang J, Shen J, et al (2013). Oncogenic MicroRNA-27a is a target for genistein in ovarian cancer cells. Curr Med Chem Anticancer Agents, 13, 1126-32.

Xu Y, Xia F, Ma L, et al (2011). MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vinorelbine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett, 310, 160-9.

Yang X, Zhang XF, Lu X, et al (2014). MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor cMet pathway. Hepatology, 59, 1874-85.

Zhang K, Chen, J, Zhou H, et al (2018). microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis, 9, 312.

Zhang LL, Guo YJ, Zhao CN, Gao JY (2015). Effects and mechanism of miR-214 on hepatocellular carcinoma. Asian Pac J Trop Med, 8, 392-8.

Zhang R, Xu J, Zhao J, Bai J (2017). Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf 1 caspase 9 complex. Oncotarget, 8, 45213-23.

Zhao X, Yang L, Hu J (2011). Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res, 30, 55.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.